Log in to MyKarger to check if you already have access to this content.
Buy
FullText & PDF
Unlimited re-access via MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *
Select
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Learn more
Rent via DeepDyve
Unlimited fulltext viewing of this article
Organize, annotate and mark up articles
Printing and downloading restrictions apply
Start free trial
Subscribe
Access to all articles of the subscribed year(s) guaranteed for 5 years
Unlimited re-access via Subscriber Login or MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
Subcription rates
Select
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
Abstract
Background: Medications used in the treatment of dermatologic conditions have been associated with squamous cell carcinoma (SCC), basal cell carcinoma (BCC), melanoma and Merkel cell carcinoma (MCC).
Objective: To examine the relationship between systemic dermatologic medications and skin cancer in the FDA Adverse Event Reporting System (FAERS).
Methods: Case control analyses were performed in FAERS from 1968-2021 to examine the reporting odds ratios (ROR) for SCC, BCC, melanoma and MCC.
Results: The oral immunosuppressants were all associated with increased ROR of SCC, BCC, melanoma and MCC. Azathioprine had the highest ROR for SCC (34.13, 95%CI 29.07-40.08), BCC (21.15, 95%CI 20.63-25.98) and MCC (44.76, 95%CI 31.52-63.55), while quinacrine and guselkumab had the highest ROR for melanoma (13.14, 95%CI 1.84-93.89 vs. 12.73, 95%CI 10.60-15.30 respectively). The TNF-a inhibitors were associated with an increased ROR for all skin cancers investigated.
Conclusions: The oral immunosuppressants and many biologic medications were associated with an increased ROR of skin cancers including TNF-alpha inhibitors (etanercept, adalimumab, infliximab), IL-23 or IL 12/23 inhibitors (ustekinumab, risankizumab), and the CD-20 inhibitor rituximab, but not dupilumab or IL-17 inhibitors.
S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
留言 (0)